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ABSTRACT
PURPOSE: To evaluate the efficacy and tolerability of a reduced rate 
of bimatoprost administration.
METHODS: Diurnal intraocular pressure (IOP) was recorded at 10 a.m., 
2 p.m. and 6 p.m. in 40 eyes of twenty Caucasian patients (age range 
56-75 years), with ocular hypertension or primary open angle glaucoma, 
at baseline and four weeks later. The right eye received daily bimatoprost, 
and in the left eye bimatoprost was administered every 48 hours at 8 
p.m. Bulbar conjunctival hyperaemia was assessed by direct observation 
by a masked observer at baseline and at week 4 and was graded as none, 
minimal, mild, or moderate or severe (0 to 4).
RESULTS: Baseline mean diurnal IOP in the right eye significantly 
(P<0.001) decreased from 25.4±2.8 to 17.8±1.8 mmHg 14 to 22 
hours after daily bimatoprost. Baseline mean diurnal IOP in the left 
eye significantly (P<0.001) decreased from 25.2±2.0 to 19.0±1.7 
mmHg 38 to 46 hours post-dose. The reduction in the right eye 
was significantly greater than in the left (P=0.02). The average con-
junctival hyperaemia after bimatoprost every 24 and 48 hours was 
graded as 2.4±1.0 and 1.8±0.8 respectively and this difference was 
significant (P<0.01).
CONCLUSION: Bimatoprost every 48 hours was less effective than 
daily bimatoprost (24.6 vs. 30% IOP decrease), but caused less 
short term conjunctival hyperaemia. This off label dose schedule 
may be proposed to patients complaining of ocular redness especia-
lly in the first weeks of treatment. 
(J Optom 2009;2:134-137 ©2009 Spanish Council of Optometry)
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coma treatment. 
RESUMEN
OBJETIVO: Evaluar la eficacia y la tolerabilidad de bimatoprost cuan-
do se reduce la frecuencia de administración.
MÉTODOS: En 40 ojos pertenecientes a veinte pacientes de raza blanca 
con hipertensión ocular o con glaucoma primario de ángulo abierto, 
y con edades comprendidas entre 56 y 75 años, se midió la presión 
intraocular (PIO) durante el día al inicio del estudio y transcurridas 
4 semanas. En el ojo derecho se administró bimatoprost una vez al 
día (cada 24 horas), y en el ojo izquierdo se administró bimatoprost 
cada 48 horas, a las 8 p.m. Se evaluó la hiperemia conjuntival bul-
bar mediante observación directa por parte de un observador (que 
desconocía la pauta administrada en cada ojo), tanto al inicio del 
estudio como en la 4ª semana del mismo. La escala utilizada (de 0 a 
4) se corresponde con “ausencia de hiperemia”, “hiperemia mínima”, 
“hiperemia leve”, “hiperemia moderada” o “hiperemia grave”.
RESULTADOS: Respecto al inicio del estudio, la PIO diurna media 
en el ojo derecho disminuyó significativamente (P<0,001), pasando 
de 25,4±2,8 a 17,8±1,8 mmHg, transcurridas entre 14 y 22 horas 
de la administración diaria de bimatoprost. Respecto al inicio del 
estudio, la PIO diurna media en el ojo izquierdo disminuyó signi-
ficativamente (P<0,001), pasando de 25,2±2,0 a 19,0±1,7 mmHg, 
transcurridas entre 38 y 46 horas de la administración de la dosis. La 
disminución en el ojo derecho resultó ser significativamente mayor 
que la observada en el ojo izquierdo (P=0,02). La hiperemia con-
juntival promedio, tras administrar bimatoprost cada 24 o cada 48 
horas, fue igual a 2,4±1,0 y a 1,8±0,8, respectivamente (P<0,01).
CONCLUSIONES: Bimatoprost cada 48 horas resultó ser menos eficaz 
que bimatoprost administrado diariamente (disminución de la PIO 
de un 24,6% frente a un 30%), pero causa menos hiperemia conjun-
tival a corto plazo. Se podría proponer esta nueva pauta posológica, 
distinta de la que aparece en la ficha técnica del producto, a aquellos 
pacientes que se quejen de tener los ojos rojos (hiperemia conjunti-
val), especialmente durante las primeras semanas de tratamiento. 
(J Optom 2009;2:134-137 ©2009 Consejo General de Colegios de 
Ópticos-Optometristas de España)
PALABRAS CLAVE: bimatoprost; conjuntiva; presión intraocular; 
tratamiento del glaucoma.
INTRODUCTION
It is well known that people over the age of 65 are at higher 
risk for glaucoma, and that the prevalence of primary open-
angle glaucoma (POAG) increases with increasing age.  POAG 
needs to be treated, and the randomized, prospective Ocular 
Hypertension Treatment Study documented the protective effect 
of the prophylactic lowering of intraocular pressure (IOP) in cases 
of ocular hypertension, which is the main risk factor for develo-
ping POAG.1 
Bimatoprost is well known for lowering IOP.1 This agent, 
which is a synthetic molecule that is structurally and pharmacologi-
cally similar to prostaglandin F2 alpha,2 is typically dosed once daily, 
and provides sustained IOP lowering over long-term use.3 However, 
ocular adverse effects,4 such as conjunctival hyperaemia, and also 
burning, eyelash lengthening and periocular pigmentation,5 may 
affect compliance or cause drug discontinuation. Hyperaemia has 
been reported in 48% of patients treated with prostaglandin analogs 
and negatively affected continuation with therapy.6 Patient edu-
cation can improve the acceptance of hyperaemia associated with 
bimatoprost therapy, which can potentially increase compliance.7 
The purpose of our study was to evaluate the IOP and the 
conjunctival hyperaemia when bimatoprost was administered less 
frequently.
METHODS
Baseline IOP was recorded at 10 a.m., 2 p.m., and 6 p.m. in 
40 eyes of twenty Caucasian patients with a mean age of 64±8.1 
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years (range 56-75) who had been newly diagnosed with either 
ocular hypertension (OH, 12 patients) or  POAG (8 patients). 
None of the patients (13 female and 7 male) had a history or 
signs of allergy or dry eye, as determined from tear-film function 
using Schirmer I and tear break-up time tests.
OH patients met the following inclusion criteria: baseli-
ne IOP exceeding 21 mmHg on at least two measurements 
on different days prior to inclusion in the study, normal 
appearance of the optic disc using slit-lamp binocular 
ophthalmoscopy, and normal Humphrey (HFA) perimetry, 
using the 24-2 Swedish Interactive Threshold Algorithm 
standard program (Carl Zeiss Meditec Dublin, CA, USA). 
Normal perimetry was defined as a mean deviation and 
pattern standard deviation (PSD) within 95% confidence 
limits and a Glaucoma Hemifield Test (GHT) result within 
normal limits.
 The diagnostic criteria for PAOG were as follows: 
baseline IOP exceeding 22 mmHg, glaucomatous optic disc 
(cup-to-disc ratio >0.4 with focal or diffuse thinning of the 
neuroretinal rim) and characteristic optic-nerve-related visual 
field loss (GHT result outside normal limits and/or PSD 
with P<0.05). All criteria were confirmed by at least two 
reliable (HFA 24-2) visual fields. Reliability was defined as 
33% or fewer false-positive or false-negative results, and 20% 
or fewer fixation losses.
 The study was in adherence to the tenets of the 
Declaration of Helsinki. Both the study and the data collec-
tion were carried out in conformity with Italian laws and 
approved by the local ethics committee. 
All subjects provided informed consent to being treated 
with bimatoprost 0.03% every 24 hours at 8 p.m. for four 
weeks in the right eye, and with bimatoprost 0.03% every 48 
hours at 8 p.m. for four weeks in the left eye. Diurnal curves 
were recorded at week 4 for both regimens on the first and 
on the second day after bimatoprost for the right and the left 
eye, respectively. 
Bulbar conjunctival hyperaemia was evaluated by the 
same masked examiner, who was unaware of the study 
design, and prior to checking the IOP using direct obser-
vation slit-lamp biomicroscopy under diffuse white illumi-
nation. IOP measurements where performed at baseline, 
prior to bimatoprost administration, and at week 4 for 
both regimens, specifically on the first and on the second 
day after bimatoprost instillation for the right and left eye, 
respectively. Hyperaemia was graded (scale from 0 to 4) as 
none, minimal, mild, moderate or severe, following Stewart 
and coworkers’ classification.8   
After verifying that the distribution of data was normal, 
we used the univariate procedure for the paired t-test and 
the frequency procedure for Mc Nemar’s test from the SAS 
FIGURE 1
Diurnal mean IOP ± standard deviation (error bars) at baseline and 4 weeks after bimatoprost administered every 24 hours in 20 right 
eyes.
FIGURE 2
Diurnal mean IOP ± standard deviation (error bars) at baseline and 4 weeks after bimatoprost administered every 48 hours (day 2) in 20 
left eyes.
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statistical software, version 9.1.3, 2004 (SAS Institute Inc, 
Cary, NC, USA).  
RESULTS
Mean (±SD) baseline diurnal IOP in the right eye signi-
ficantly (P<0.001) decreased from 25.4±2.8 (range 22-28) to 
17.8±1.3 (range 16-20) mmHg (means of the three measu-
rements) 14 to 22 hours after the daily bimatoprost dose. As 
regards every-other-day bimatoprost administration, baseline 
mean diurnal IOP in the left eye significantly (P<0.001) 
decreased from 25.2± 2.0 (range 23-27) to 19.0±1.5 (range 
17-22) mmHg, as measured 38 to 46 hours post-dose. There 
was a significant (P=0.02, paired t-test) difference of IOP bet-
ween the two dosing regimens (see Figure 1, Table 1).The mean 
IOP drop was -7.6 (30% decrease) and -6.2 mmHg (24.6% 
decrease) following daily and every-other-day bimatoprost 
instillation, respectively. In 10 right (50%) and 5 left (25%) 
eyes the IOP was below 18 mmHg; 10 (50%) and 15 (75%) 
of the right and left eyes, respectively, had an IOP greater than 
17 mmHg (P=0.06 from Mc Nemar’s test) (see Table 1). 
The baseline bulbar conjunctival hyperaemia evaluated 
by means of direct observation with a slit-lamp (1.1±0.8 
for the right eyes and 1.2±0.6 for the left eyes) increased 
(P<0.001) as a result of bimatoprost administrations with 
both the 24-hour (2.4±1.0) and the 48-hour (1.8±1.2) sche-
dules, but the difference between the hyperaemia for the two 
administration rates was found to be statistically significant 
(P<0.01) (see Table 2). Six (30%) right eyes and two (10%) 
left eyes developed moderate conjunctival hyperaemia under 
the 24- and the 48-hour bimatoprost protocol, respectively. 
All patients completed the study; but three patients with 
moderate conjunctival hyperaemia were switched to another 
IOP-lowering therapy in the follow-up, because they no lon-
ger tolerated the conjunctival hyperaemia. 
DISCUSSION
Our results, based on a small series of patients with limited 
follow up, indicate that mean IOP can be effectively lowered 
by bimatoprost administered either every 24 or 48  hours. The 
IOP-lowering action of bimatoprost, monitored in our study 
for up to 46 hours after the last dose, parallels the effect of 
travoprost 12 and 44 hours post dose, with a reported IOP 
reduction of 9.1 and 7.7 mmHg, respectively.9  
The average 24.6% IOP decrease 38 to 46 hours post-
dose in our series was significantly different (P=0.02), com-
pared with the average 30% IOP decrease 14 to 22 hours 
post-dose. Thus, on average, a significantly better IOP con-
trol was achieved in the right eye relative to that attained in 
the left eye, even though we did not establish target IOP for 
each patient. However, an analysis of the lowest and highest 
IOP values in both treated eyes, with a cut-off IOP at 17 
mmHg, reached borderline significance only (P=0.06). 
It cannot be ruled out that the daily dosing on the right 
eye could have affected the left eye’s IOP. The mean IOP 
change in the fellow eye was –0.64±3.05 mmHg in a  mono-
cular trial where 59% of subjects received a prostaglandin 
analog in one eye only.10 However, latanoprost, and reasona-
bly any prostaglandin analog, has little (if any) contralateral 
IOP effect, due to its rapid systemic metabolism.11  
A possible waning effect of bimatoprost closer to the 48 
hours, immediately pre-dosing, and nocturnal fluctuation in 
IOP were not checked. According to a recent meta-analysis, 
bimatoprost and travoprost showed the greatest 24-hour IOP 
reduction among monotherapy treatments (prostaglandins, 
betablockers, carbonic anhydrase inhibitors) for POAG/OH 
patients. Both bimatoprost and travoprost did not demons-
trate lower nighttime pressure values than daytime ones.12 
Last but not least, it is worthwhile to note that the cost per 
treatment success in the US, especially at target pressures <15 
mmHg, is generally lower for bimatoprost than for either 
timolol, latanoprost or timolol/dorzolamide.13
The ocular redness found in two different studies after 
the fixed combination of bimatoprost 0.03%+0.5%14-15 was 
similar to that observed in our patients at the reduced rate of 
administration of bimatoprost (8.5% vs. 10% of conjunctival 
hyperaemia and 1.62 vs. 1.8 of hyperaemia grade for the fixed 
combination and for bimatoprost every 48 hours, respective-
ly). However, there is evidence that in healthy subjects, the 
duration of conjunctival hyperaemia may be significantly 
TABLE 1 
Average (SD) IOP measured in twenty patients, both at baseline 
and 4 weeks after bimatoprost instillation every 24 or 48 hours
 IOP mmHg P Value
Baseline (right eye) 25.4 (2.8) 
24 h bimatoprost 17.8 (1.3) <0.001*
Baseline (left eye) 25.2 (2.0)  
48 h bimatoprost 19.0 (1.5) <0.001*
24 h bimatoprost 17.8 (1.3) 
48 h bimatoprost 19.0 (1.5) 0.02**    
24 hour bimatoprost <18 in 10 eyes and  
 >17 in 10 eyes 
48 hour bimatoprost <18 in 5 eyes and  
 >17 in 15 eyes 0.06**
*P-value compared to baseline, **P-value for schedule comparison.
TABLE 2 
Average (SD) bulbar conjunctival hyperaemia rating after bimato-
prost instillation every 24 or 48 hours
 Bulbar hyperaemia P Value
Baseline (right eye) 1.1 (0.8) 
24 h bimatoprost 2.4 (1.0) <0.001*
Baseline (left eye) 1.2 (0.6) 
48 h bimatoprost 1.8 (1.2) <0.001*
24 h bimatoprost 2.4 (1.0) 
48 h bimatoprost 1.8 (1.2) <0.01**
*P-value compared to baseline, **P-value for schedule comparison.
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shorter with latanoprost (lasting five days), compared with 
bimatoprost or travoprost.5 The findings of a meta-analysis 
in POAG/OH patients suggest a greater efficacy of bima-
toprost, compared with that of latanoprost and travoprost, 
although the incidence of hyperemia was lower with the 
latter two agents.16 As conjunctival hyperaemia with bimato-
prost is highest during the first weeks and then diminishes by 
three months17, a reduced dose of bimatoprost may be better 
tolerated in the first weeks, whereas the standard regimen 
could be recommended later. We are aware that the method 
of subjectively grading ocular hyperaemia from direct obser-
vation18 or colour photographs8 is less sensitive and reliable 
than objective image analysis,19 which requires appropriate 
software and instrumentation unavailable to us.
Adherence and persistence is likely to be worse with pres-
criptions other than daily dosing. On the other hand, this 
study indicates that sporadic omission of a daily dose would 
not lead to clinically relevant IOP fluctuations. Eyelash growth 
and increased pigmentation of the iris and periocular skin were 
not noticed in our short-term study but it is reasonable to sup-
pose that less frequent administration of bimatoprost should 
reduce these late side effects, as well as the effects of cumulative 
exposure of the ocular surface to cytotoxic preservatives such as 
benzalkonium chloride.20 
Limitations of the study included: a limited number of 
patients, the subjective grading of ocular hyperaemia from 
direct observation, and the absence of investigation about the 
long-term effects on hyperaemia or other adverse effects due 
to both regimens of administration. 
To summarize, bimatoprost every 48 hours was moderately 
less effective (on the second day) than daily bimatoprost, but 
caused less short-term conjunctival hyperaemia. Since bimato-
prost-induced conjunctival hyperaemia is reported to be higher 
in the first month, this reduced dosing schedule may be propo-
sed, especially in the first weeks of treatment to selected patients; 
those who start on a daily dose of bimatoprost 0.03%, show 
satisfactory IOP decrease but complain of ocular redness.
REFERENCES
  1.  Cantor LB, Hoop J, Morgan L, Wudunn D, Catoira Y. Bimatoprost- 
Travoprost Study Group. Intraocular pressure-lowering efficacy of 
bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma 
or ocular hypertension. Br J Ophthalmol. 2006;90:1370-1373.
  2.  Arranz-Marquez E, Teus MA. Prostanoids for the management of glau-
coma. Expert Opin Drug Saf. 2008;7:801-808.
  3.  Williams RD, Cohen JS, Gross RL, Liu CC, Safyan E, Batoosingh AL; 
Bimatoprost Study Group. Long term efficacy and safety of bimato-
prost for intraocular pressure lowering in glaucoma and ocular hyper-
tension:year 4. Br J Ophthalmol. 2008;92:1387-1392.
  4.  Hollò G. The side effects of prostaglandin analogues. Expert Opin Drug 
Saf. 2007;6:45-52.
  5.  Centofanti M, Oddone F, Chimenti S, Tanga L, Citarella L, Manni G. 
Prevention of dermatologic side effects of bimatoprost 0.03% topical 
therapy. Am J Ophthalmol. 2006;142:1059-1060.
  6.  Zimmermann TJ, Hahn SR, Gelb L, Tan H, Kim EE. The impact of 
ocular adverse effects in patients treated with topical prostaglandin ana-
logs: changes in prescription and patient persistence. J Ocul Pharmacol 
Ther. 2009;25:145-152.
  7.  Trattler W, Noecker RJ, Earl ML. A multicentre evaluation of the effect 
of patient education on the acceptance of hyperemia associated with 
bimatoprost therapy for glaucoma or ocular hypertension. Adv Ther. 
2008;25:179-189.
  8.  Stewart WC, Kolker AE, Stewart JA, Leech J, Jackson AL. Conjunctival 
hyperemia in healthy subjects after short- term dosing with latanoprost, 
bimatoprost and travoprost. Am J Ophthalmol. 2003;135:314-320.
  9.  Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal 
ocular hypotensive efficacy of travoprost and latanoprost over a 44-
hour period in patients with elevated intraocular pressure. Clin Ther. 
2004;26:84-91.
10.  Chaudhary O, Adelman RA, Shields MB. Predicting response to 
glaucoma therapy in one eye based on response in the fellow eye. The 
monocular trial. Arch Ophthalmol. 2008;126:1216-1220.
11.  Realini T, Fechtner RD, Atreides S, Gallance S. The uniocular drug trial 
and second-eye response to glaucoma medications. Ophthalmology. 
111:421-426.
12.  Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-
hour intraocular pressure studies evaluating the efficacy of glaucoma 
medicines. Ophthalmology. 2008;115:1117-1122.
13.  Goldberg LD, Walt J. Cost considerations in the medical management 
of glaucoma in the US: estimated yearly costs and cost effectiveness of 
bimatoprost compared with other medications. Pharmacoeconomics. 
2006;24:251-264.  
14.  Hommer A, Ganfort Investigators Group I. A double masked, ran-
domized, parallel comparison of a fixed combination of bimatoprost 
0.03% timolol 0.5% with non-fixed combination use in patients 
with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17: 
53-62.
15.  Martinez A, Sanchez M. A comparison of the safety and intraocular 
pressure lowering of bimatoprost/timolol fixed combination versus 
latanoprost/timolol fixed combination in patients with open angle 
glaucoma. Curr Med Res Opin. 2007;23:1025-1032.
16.  Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglan-
din analogs: a meta-analysis of randomized controlled clinical trials. J 
Glaucoma. 2008;17:667-673.
17.  Higginbotham EJ, Schuman JS, Goldberg I, et al. One-year randomi-
zed study comparing bimatoprost and timolol in glaucoma and ocular 
hypertension. Arch Ophthalmol. 2002;120:1286-1293.
18.  Murphy PJ, Lau JS, Sim MM, Woods RL. How red is a white eye? Clinical 
grading of normal conjunctival hyperaemia. Eye. 2007;21:633-638.
19.  Peterson RC, Wolffsohn JS. Sensitivity and reliability of objective image 
analysis compared to subjective grading of bulbar hyperaemia. Br J 
Ophthalmol. 2007;91:1464-1466.
20.  Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignolo-
Baudouin F. In vitro studies of inflammatory potential and toxicity 
profile of latanoprost, travoprost, and bimatoprost in conjunctiva-
derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:2444-
2450.
